19,900 Shares in TG Therapeutics, Inc. $TGTX Acquired by Strs Ohio

Key Points

• Strs Ohio acquired a new investment position in TG Therapeutics, purchasing 19,900 shares valued at approximately $785,000 in the first quarter.
• The company reported $0.17 earnings per share, which missed analysts' expectations of $0.32, although revenue rose 92.1% year-over-year to $141.15 million.
• Analysts have given TG Therapeutics a consensus rating of "Moderate Buy" with a target price of $48.00, indicating optimism about the stock's future performance.

Strs Ohio bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 19,900 shares of the biopharmaceutical company's stock, valued at approximately $785,000.

A number of other institutional investors have also modified their holdings of TGTX. Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $30,000. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares in the last quarter. Golden State Wealth Management LLC raised its stake in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares in the last quarter. SVB Wealth LLC acquired a new stake in TG Therapeutics during the first quarter worth about $37,000. Finally, USA Financial Formulas acquired a new stake in TG Therapeutics during the first quarter worth about $57,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 20,852 shares of the firm's stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 10.64% of the company's stock.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded up $2.37 on Monday, hitting $34.74. The company had a trading volume of 2,201,623 shares, compared to its average volume of 2,455,476. The company has a market cap of $5.51 billion, a PE ratio of 93.62 and a beta of 1.88. TG Therapeutics, Inc. has a 52 week low of $21.16 and a 52 week high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The business has a 50-day simple moving average of $31.91 and a 200-day simple moving average of $35.65.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company's quarterly revenue was up 92.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

TGTX has been the topic of several research reports. The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. B. Riley increased their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a "buy" rating in a research note on Wednesday, September 17th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $48.00.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.